Janux Therapeutics, Inc. Stock Price, News & Analysis

Janux (NASDAQ: JANX) reported updated interim Phase 1 data for JANX007, a PSMA-directed TRACTr in mCRPC, with data cut-off Oct 15, 2025. Across Phase 1a/b, 109 patients were treated; Phase 1a patients had a median of 4 prior lines of therapy while Phase 1b enrolled taxane-naïve patients.

Key efficacy signals include confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients and rPFS of 7.9–8.9 months. Taxane-naïve expansion showed rapid, deep PSA reductions. Safety was described as manageable with CRS primarily grade 1–2 limited to cycle 1 and an identified CRS mitigation strategy. Janux plans monotherapy and darolutamide combinations and will evaluate PARP inhibitor–refractory patients.

Janux Therapeutics (NASDAQ: JANX) will host a virtual event on December 1, 2025 at 4:30 PM ET where CEO David Campbell, Ph.D. will present updated clinical data for JANX007.

The presentation will emphasize Phase 1a dose-escalation results and secondarily cover Phase 1b expansion data in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), followed by a live analyst Q&A. Registration is required to attend.

The release also summarizes Janux's development pipeline including JANX008 (EGFR TRACTr), additional CD3 TRACTr and CD28 TRACIr programs, a PSMA-TRACIr intended for combination use with JANX007, a TROP2-TRACTr, and a CD19-ARM program targeting autoimmune disease.

Janux Therapeutics (NASDAQ: JANX) reported third-quarter 2025 results and a business update on November 6, 2025. Key points: cash and short-term investments of $989.0 million as of September 30, 2025; ongoing enrollment in first-in-human Phase 1 trials for JANX007 (mCRPC) and JANX008 (advanced/metastatic solid tumors); additional JANX007 and JANX008 data expected in the fourth quarter of 2025.

Quarterly results: R&D expense $34.6M (Q3 2025) vs $18.6M (Q3 2024); G&A expense $10.6M vs $17.7M; net loss $24.3M vs $28.1M. Pipeline updates include multiple TRACTr, TRACIr and ARM candidates and planned clinic entries next year.

Janux Therapeutics (NASDAQ:JANX) reported Q2 2025 financial results and business updates, highlighting progress across its TRACTr, TRACIr, and ARM platforms. The company maintains a strong financial position with $996.0 million in cash and investments, down slightly from $1.03 billion at year-end 2024.

Key developments include ongoing enrollment in Phase 1 trials for JANX007 (targeting PSMA in mCRPC) and JANX008 (targeting EGFR in multiple solid tumors). Janux received a $10 million milestone payment from Merck following the first patient dosing in their lead collaboration program. The company's July R&D Day showcased new candidates including a PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM for autoimmune diseases.

Q2 financial results showed increased R&D expenses of $34.7 million and a net loss of $33.9 million, reflecting expanded clinical development activities.

Janux Therapeutics (Nasdaq: JANX) has achieved a significant clinical milestone in its TRACTr collaboration with Merck, triggering a $10 million milestone payment. The achievement marks the dosing of the first patient in their collaborative program, stemming from their December 2020 partnership.

The company is advancing multiple clinical programs, including JANX007, a PSMA-targeting TRACTr in Phase 1 trials for mCRPC, and JANX008, an EGFR-targeting TRACTr being studied across multiple solid cancers. Janux is also developing additional CD3-based TRACTr and CD28-based TRACIr programs, including a PSMA-TRACIr and TROP2-TRACTr, alongside their first ARM platform program targeting CD19 for autoimmune diseases.

Janux Therapeutics (NASDAQ:JANX) showcased its pipeline progress during its virtual R&D Day, highlighting three key platforms: TRACTr, TRACIr, and ARM. The company announced advancement of its PSMA-TRACIr program, designed to enhance JANX007's efficacy in prostate cancer treatment, with clinical trials expected in H2 2026.

Janux introduced its TROP2-TRACTr program for multiple solid tumors, with IND-enabling activities planned for H2 2025. The company also revealed its novel CD19-ARM platform for autoimmune diseases, demonstrating promising preclinical results in B-cell depletion with first-in-human trials anticipated in H1 2026.

The company's pipeline includes two clinical-stage candidates: JANX007 for metastatic castration-resistant prostate cancer and JANX008 targeting EGFR in multiple solid cancers.

Janux Therapeutics (Nasdaq: JANX), a clinical-stage biopharmaceutical company, has announced a virtual R&D Day scheduled for July 24, 2025, at 1:30 PM PT. The event will showcase management presentations focusing on new preclinical pipeline candidates advancing to clinical trials.

The company specializes in novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Currently, Janux has two clinical candidates: JANX007, targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR in multiple solid cancers. The company is also developing additional TRACTr and TRACIr programs at various development stages.

Janux Therapeutics (NASDAQ: JANX) has appointed Janeen Doyle, MBA as Chief Corporate and Business Development Officer. Doyle brings over 24 years of experience across biotech, pharma, and venture ecosystems. She joins from Flagship Pioneering, where she served as Senior Partner and SVP of Corporate Partnerships. Previously, she spent 15+ years at Bristol Myers Squibb and Celgene, most recently as SVP of Strategy & Business Development, overseeing 300+ strategic collaborations.

Janux is advancing its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. The company has two clinical candidates: JANX007, targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR in multiple solid cancers including colorectal carcinoma and lung cancer.

Janux Therapeutics (NASDAQ: JANX) has reported its Q1 2025 financial results and provided key business updates. The company has initiated Phase 1b expansion studies for JANX007 in taxane-naïve mCRPC patients, with updated results showing a median radiographic progression-free survival (rPFS) of 7.5 months across 16 patients. For patients treated at higher doses (6mg and 9mg), the median rPFS reached 7.9 months. The company plans to initiate three additional Phase 1b expansion studies for JANX007 in different mCRPC patient populations. Financially, Janux maintains a strong position with $1.01 billion in cash and investments as of March 31, 2025. The company reported R&D expenses of $25.1 million and a net loss of $23.5 million for Q1 2025. Updates on both JANX007 and JANX008 clinical programs are expected in H2 2025, and the company plans to host an R&D Day in mid-2025 to showcase its preclinical pipeline.